Sagimet Biosciences (SGMT) Balance Sheet: Assets & Liabilities

Sagimet Biosciences (SGMT) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Sagimet Biosciences reported total assets of $116.48M and total liabilities of $5.10M. Shareholders' equity was $111.38M, down 28.5% from $155.81M a year earlier. Total debt stood at $78.00K against $113.12M in cash and short-term investments, a net cash position of $113.05M. That puts debt-to-equity at 0.00, compared with 0.00 a year earlier.

Sagimet Biosciences Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Sagimet Biosciences Inc. (SGMT) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Current Assets
Cash and Cash Equivalents	35.02	75.84	75.14	0.16	56.73	68.70	10.21
Short-Term Investments	78.10	75.41	19.76	32.19	0.00	0.00	0.00
Cash & Short-Term Investments	113.12	151.25	94.90	32.35	56.73	68.70	10.21
Accounts Receivable	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Current Assets	3.28	1.52	1.75	0.45	0.08	0.04	0.60
Total Current Assets	116.40	152.77	96.65	32.79	58.66	68.74	10.82
Non-Current Assets
Property, Plant & Equipment (Net)	0.08	0.08	0.07	0.21	0.34	0.19	0.32
Long-Term Investments	0.00	7.41	0.00	0.00	0.00	0.00	0.00
Other Non-Current Assets	0.00	0.00	0.00	0.03	0.03	0.03	0.03
Total Non-Current Assets	0.08	7.49	0.07	0.24	0.37	0.22	0.35
Total Assets	116.48	160.26	96.72	33.03	59.03	68.96	11.16
Current Liabilities
Accounts Payable	1.31	1.43	0.19	1.13	0.76	0.51	1.20
Short-Term Debt	0.08	0.08	0.07	0.13	0.12	0.15	0.13
Accrued Liabilities	3.69	2.95	5.40	3.96	1.37	1.01	-
Other Current Liabilities	3.71	0.01	5.40	4.02	0.19	1.25	0.75
Total Current Liabilities	5.10	4.45	5.65	5.28	2.44	1.91	2.08
Non-Current Liabilities
Long-Term Debt	0.00	0.00	0.00	0.08	0.22	0.07	0.21
Other Non-Current Liabilities	0.00	0.00	0.00	214.62	214.63	202.89	134.19
Total Non-Current Liabilities	0.00	0.00	0.00	214.70	214.85	202.96	134.40
Total Liabilities	5.10	4.45	5.65	219.98	217.29	204.87	136.48
Stockholders' Equity
Common Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Retained Earnings	-346.35	-295.31	-249.74	-221.87	-191.37	-166.93	-155.56
Accumulated Other Comprehensive Income	0.12	0.23	0.03	-0.08	0.00	0.00	0.00
Additional Paid-in Capital	457.61	450.88	340.78	35.00	33.11	31.02	30.24
Shares Outstanding	32.52	32.20	22.90	22.17	22.17	-	-
Total Stockholders' Equity	111.38	155.81	91.07	-186.95	-158.26	-135.91	-125.32
Total Liabilities & Equity	116.48	160.26	96.72	33.03	59.03	68.96	11.16

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Sagimet Biosciences Balance Sheet

How much debt does Sagimet Biosciences have?

Sagimet Biosciences had total debt of $78.00K as of Dec 31, 2025, against $113.12M in cash and short-term investments. Its debt-to-equity ratio was 0.00. Total debt was $78.00K a year earlier.

What are Sagimet Biosciences's total assets?

Sagimet Biosciences reported total assets of $116.48M as of Dec 31, 2025, down 27.3% from $160.26M a year earlier. Total liabilities were $5.10M.

What is Sagimet Biosciences's shareholders' equity?

Sagimet Biosciences's shareholders' equity was $111.38M as of Dec 31, 2025, or about $3.42 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition